MITAKY™ − GLOBAL HEALING BY JAPANESE REGENERATIVE MEDICINES🧬 & ROBOTICS📡
"Made in Japan"
&
"Made by Technologies"
Latest News
April 10, 2024
04
Featured Products & Services
Japanese Autologous Adipose Tissue-Derived Stem Cell Therapy
Japanese Autologous Adipose Tissue-Derived Stem Cell (ADSC) Therapy is an advanced form of regenerative medicine facilitated through MITAKY™ Group’s network of accredited medical centres in Japan. The ADSC therapy involves collecting stem cells from a patient’s own adipose (fat) tissue, processing them within a certified CPC (Cell Processing Centre), and re-infusing them into the patient’s body to promote healing and regeneration of damaged tissues. The use of the patient’s own cells (meanings ‘Autologous’) minimises the risk of rejection and eliminates ethical concerns, ensuring a safe and effective treatment experience.
MITAKY™ Group is a premier facilitator of high-quality medical and healthcare tourism support services in Japan. Patients connected through MITAKY™ Group can access the ADSC therapy for the following conditions: Stroke, Anti ageing, AGA, Arteriosclerosis, Dementia (Parkinson, Alzheimer), Knee pain and many other rare symptoms.
Japanese Technology Transfer Professional Services
Technology transfer is the process where an organisation possessing an advanced technology provides it to a developing organisation (both private & governmental), facilitating the exchange of know-how, knowledge, skills, and innovations to enhance their capabilities.
Japanese technologies, renowned for innovation, precision, and reliability, offer significant global advantages. Our Japanese partners hold exceptional research findings, know-how, and patents in various emerged technologies: Regenerative Medical Technologies (stem cell and immune cell cultivations), Robotics, AI, Renewable energy, Biotechnology, Nanotechnology, and Environmental technologies.
MITAKY™ Group is confident in our ability to share, transfer and advise these technologies to partners globally, either in full or in part, including setting up GMP laboratories, cell culturing know-how, quality controlling, patient counselling, ultimately applying the therapies in patient treatment; or advising in development, production, high-end equipment logistics, and others.
Japanese Autologous Immune Cell Therapy for Cancer (Immunotherapy)
Japanese Autologous Immune Cell Therapy or Cancer Immunotherapy is a personalised cancer treatment that utilises the patient’s own immune cells to combat cancer. This therapy involves extracting immune cells, such as T-cells and Natural Killer (NK) cells, from the patient’s own blood cells, activating and cultivating them in a certified CPC, and then reinfusing them back into the patient’s body. The goal is to enhance the immune system’s ability to recognise and destroy cancer cells.
This approach is considered the 4th modality of cancer treatment, complementing surgery, radiotherapy, and chemotherapy. It offers a targeted method to eliminate cancer cells while minimising damage to healthy tissues. Autologous means using the patient’s own cells, by this, the therapy reduces the risk of immune rejection and adverse reactions, providing an effective treatment option.
MITAKY™ Group is a premier facilitator of high-quality medical and healthcare tourism support services in Japan. Patients connected through MITAKY™ Group can access the immune cell therapy for cancers prevention/treatment such as: Lung cancer, Breast cancer, Colorectal cancer, Ovarian cancer, Pancreatic cancer, Prostate cancer, Liver cancer, Gastric cancer and many others.